

Table of Metrics with ease of reporting

*= currently available/tracked

Category	Metric	Notes
Screening and Baseline	Autoantibodies <ul style="list-style-type: none"> • Method* • Age at screening* • Dates Setting (research / clinic)* Other autoimmunity* Source of Referral* DKA at Stage 3 diagnosis*	Dates for stage 1, 2, 3 Family history or autoimmunity
Therapies	Therapy (yes/no) <ul style="list-style-type: none"> • Timing of discussion Type of Therapy* Timing related to Stage 3 diagnosis* Related labs* Protocol <ul style="list-style-type: none"> • Protocol used, any deviation • Inpatient vs home vs hybrid • Age at treatment • Side effects 	Reason declined if No Infections, CBC/CMP
Beta Cell	C-peptide Total Daily Dose of Insulin* (units/kg/day) Insulin dose adjusted HbA1c *	MMTT vs random vs after a home meal; standardize <0.25 units/kg/day HbA1c + (4*TDD)
Immunologic	Autoantibody number and type* Repeat testing	
Metabolic	Hemoglobin A1c (%)* CGM Metrics <ul style="list-style-type: none"> • TIR* • Time in Tight Range (TiTR, 70-140 mg/dL) • Time above 140 mg/dL (TA140) • TBR/hypoglycemia* • Glycemic variability - CV* 	>10% TA140 associated with high risk of progression to Stage 3 T1D within 1 year ¹²
Patient Centered	Race/ethnicity* Insurance* BMI* Psychosocial screening* DKA or severe hypoglycemia after DMT*	